Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Can modified chemotherapy treatment improve B-non Hodgkin lymphoma survival rates?

Posted by on Mar 5, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if a modified chemotherapy treatment can improve outcomes for patients with B-non Hodgkin lymphoma (B-NHL), in lower income countries. This study concluded that reduced-intensity chemotherapy can result in long term survival rates in these patients. Some background B–non-Hodgkin lymphoma (B-NHL) is also known as...

Read More

BEAM versus BEAC high-dose chemotherapy for patients with non-Hodgkin’s lymphoma

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of two high-dose chemotherapy regimens for patients with non-Hodgkin’s lymphoma (NHL) before autologous stem cell transplantation (ASCT). This study concluded that the outcomes were similar between both regimens. Some background High-dose chemotherapy is typically used before ASCT to get rid of any...

Read More

Predicting outcomes using the MIPI score for newly-diagnosed patients with MCL

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the use of the MIPI score for patients with newly diagnosed mantle cell lymphoma (MCL). This study concluded that the MIPI score may better predict prognosis for these patients. Some background MCL is a type of non-Hodgkin’s lymphoma that significantly differs between individual patients. The MCL international...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients.  Some background Mantle cell...

Read More

Evaluating ibrutinib plus nivolumab for relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Feb 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for high-risk...

Read More

Are patients with follicular lymphoma more likely to develop congestive heart failure?

Posted by on Feb 23, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if patients being treated for follicular lymphoma (FL) have an increased risk of developing congestive heart failure (CHF).  This study concluded that there is an increased risk of developing CHF in patients diagnosed with FL who received anthracyclines between the ages of 66-75.  Some background FL...

Read More

Evaluating the impact of quality of life at diagnosis on patient outcomes for aggressive lymphoma

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated whether quality of life (QOL) scores impact outcomes for patients with aggressive lymphoma. This study concluded that QOL scores at diagnosis may predict survival outcomes for these patients. Some background The International Prognostic Index (IPI) is the most widely used tool to predict survival outcomes for...

Read More

Predicting the effects of stem cell transplant in older patients with non-Hodgkin lymphoma.

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of stem cell transplant for non-Hodgkin lymphoma (NHL) in older patients. The main finding was that patients who responded to chemotherapy had better outcomes after stem cell transplant. Some background Stem cell transplant is often used to treat NHL. This involves the transfer of healthy cells to a...

Read More

Comparing outcomes after adding two doses of rituximab to R-CHOP chemotherapy for aggressive B-cell lymphoma

Posted by on Jan 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of six versus eight doses of rituximab (Rituxan) in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with aggressive B-cell lymphoma. This study concluded that adding two extra doses of rituximab to R-CHOP had similar outcomes in these...

Read More

Long-term outcomes of radioimmunotherapy for patients with follicular lymphoma

Posted by on Jan 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of radioimmunotherapy (RIT) in patients with follicular lymphoma (FL). This study concluded that RIT is a safe and effective long-term treatment option for these patients. Some background FL is the most common type of non-Hodgkin’s lymphoma. The current standard first-line treatment for...

Read More